Stockscreener 앱 받기
0.561
2.89%
0.021
전일 마감가:
$0.54
열려 있는:
$0.5465
하루 거래량:
31,533
Relative Volume:
0.05
시가총액:
$15.25M
수익:
$5.61M
순이익/손실:
$-55.45M
주가수익비율:
-0.2183
EPS:
-2.5703
순현금흐름:
$-42.35M
1주 성능:
-0.05%
1개월 성능:
-20.67%
6개월 성능:
-49.49%
1년 성능:
-29.68%
1일 변동 폭
$0.54
$0.562
1주일 범위
$0.5307
$0.5999
52주 변동 폭
$0.476
$2.48
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
명칭
Citius Pharmaceuticals Inc
전화
(908) 967-6676
주소
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.5556 | 14.82M | 5.61M | -55.45M | -42.35M | -2.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
450.65 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.75 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.14 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.91 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.41 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
Citius Pharmaceuticals Inc 주식(CTXR)의 최신 뉴스
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan
Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan
[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks
Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
Citius Oncology (NASDAQ: CTXR) shares early Phase 1 LYMPHIR cancer data - Stock Titan
Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - BioSpace
Citius Oncology presents study data on LYMPHIR combination By Investing.com - Investing.com Australia
Citius Oncology presents study data on LYMPHIR combination - Investing.com
LYMPHIR combo study finds 24% response, disease control up to 35 months - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies – Company AnnouncementFT.com - Financial Times
Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - simplywall.st
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - marketscreener.com
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
TENK News & Events - Intellectia AI
Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants - Stock Titan
Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps - Stock Titan
5 Best Rated Penny Stocks to Buy According to Wall Street Analysts - Insider Monkey
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances - Stock Titan
H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Citius Pharmaceuticals Reports Increased Losses in Q2 FY 2026 - Intellectia AI
Citius Pharmaceuticals Price Target Announced at $4.00/Share by HC Wainwright & Co. - Moomoo
H.C. Wainwright Initiates Citius Pharmaceuticals(CTXR.US) With Buy Rating, Announces Target Price $4 - Moomoo
CTXR Assumes Buy Rating by HC Wainwright & Co. -- Price Target a - GuruFocus
Citius Pharmaceuticals (CTXR) price target increased by 20.00% to 6.12 - MSN
Citius Pharmaceuticals Q2 Net Income USD -21. - Moomoo
Is Citius Pharmaceuticals (CTXR) Undervalued After Q2 FY2026 Upd - GuruFocus
CTXR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Citius Pharmaceuticals reports $5.6M H1 revenue from LYMPHIR; Q2 net loss $21.2M - TradingView
CTXR: $5.6M in LYMPHIR revenue, 80% gross margin, $21.2M Q2 net loss, $41.5M new financing - TradingView
[8-K] CITIUS ONCOLOGY, INC. Reports Material Event - Stock Titan
Citius Pharmaceuticals Q2 revenue rises on LYMPHIR launch - TradingView
Citius Pharmaceuticals (CTXR) logs $5.6M LYMPHIR sales, deeper losses in Q2 2026 - Stock Titan
Citius Pharmaceuticals, Inc. 3Q FY2026: Revenue $1.67M, EPS $(0.95) — 10-Q Summary - TradingView
CTXR: LYMPHIR launch spurred revenue growth, but losses rose sharply due to a major contract termination - TradingView
Citius Oncology 2Q Loss/Shr 27c >CTOR - Moomoo
Citius Pharmaceuticals (CTXR) starts LYMPHIR sales but faces heavy loss and going concern risk - Stock Titan
Citius Oncology (NASDAQ: CTOR) flags going concern, adds $25.0 million loan - Stock Titan
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - Financial Times
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Quantisnow
CTXR Stock Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Pharmaceuticals secures $5M through equity offering - MSN
TradingKey - TradingKey
Number of shareholders of Citius Pharmaceuticals Inc – GETTEX:47N0 - TradingView
Citius Pharmaceuticals Announces Third Amendment to Promissory Note with Citius Oncology – SEC Filing Details - Minichart
Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility - TipRanks
Citius Pharmaceuticals (CTXR) adds $0.90 share conversion to $3.8M note - Stock Titan
CTXR | Citius Pharmaceuticals Inc. Common Insider Trading - Quiver Quantitative
Citius Pharmaceuticals Inc (CTXR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.61%
자본화:
|
볼륨(24시간):